Brazilian Thalassemia association protocol for iron chelation therapy in patients under regular transfusion

Revista Brasileira de Hematologia e Hemoterapia

Volumn 35, Issue 6, 2013, Pages 428-434

  Veríssimo, Monica Pinheiro de Almeida ^a   Loggetto, Sandra Regina ^b   Fabron Junior, Antonio ^c   Baldanzi, Giorgio Roberto ^d   Hamerschlak, Nelson ^e   Fernandes, Juliano Lara ^f   Araujo, Aderson da Silva ^g   Lobo, Clarisse Lopes de Castro ^h   Fertrin, Kleber Yotsumoto ⁱ   Berdoukas, Vasilios Antonios ^j   Galanello, Renzo ^k  

^a Centro Infantil de Investigações   (Brazil)

^b Centro de Otorrinolaringologia de São Paulo Complexo Hospitalar Edmundo Vasconcelos   (Brazil)

^c Centro de Hematologia e Hemoterapia do Paraná HEMEPAR ^*

^d Centro de Hematologia e Hemoterapia Do Paraná HEMEPAR   (Brazil)

^e HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^f Jose Michel Kalaf Research Institute   (Brazil)

^g Hospital de Hematologia e Hemoterapia de Pernambuco HEMOPE   (Brazil)

^h Instituto de Hematologia 'Arthur de Siqueira Cavalcanti' HEMORIO   (Brazil)

ⁱ UNIVERSITY OF CAMPINAS   (Brazil)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^k UNIVERSITY OF CAGLIARI   (Italy)

more..

Author keywords

Beta thalassemia; Blood transfusion; Brazil; Chelation therapy; Deferasirox; Deferiprone; Iron chelating agents; Iron overload; Iron metabolism; Magnetic resonance imaging; Practice guidelines as topic; Protocols

Indexed keywords

EID: 84893241549     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: 10.5581/1516-8484.20130106     Document Type: Article

References (56)

1. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-93. Comment in: Haematologica. 2004;89(10):1157-9.
2. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR; Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood. 2004;104(1):34-9.
3. Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961-8. Comment in: Circulation. 2009;120(20):1937-9.
4. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567-73. Comment in: N Engl J Med. 1995;332(4):270-1. N Engl J Med. 1995;332(4):271-2. N Engl J Med. 1994;331(9):609-10.
5. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331(9):574-8. Comment in: N Engl J Med. 1995;332(4):271; author reply 272-3; N Engl J Med. 1995;332(4):271-2; author reply 272-3; N Engl J Med. 1994; 331(9):609-10.
6. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26-36.
7. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355(9220):2051-2.
8. Anderson LJ, Westwood MA, Prescott E, Walker JM, Pennell DJ, Wonke B. Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol. 2006;115(1-2):106-8.
9. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102(1):17-24.
10. Victor Hoffbrand A. Deferiprone therapy for transfusional iron overload. Best Pract Res Clin Haematol. 2005;18(2):299-317.
11. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998;103(2):361-4. Comment in: Br J Haematol. 1999;106(1):252-3.
12. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003;121(1):187-9.
13. Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica. 2003;88(12):1423-5.
14. Wu KH, Chang JS, Tsai CH, Peng CT. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Ann Hematol. 2004;83(7):471-3.
15. Alymara V, Bourantas D, Chaidos A, Bouranta P, Gouva M, Vassou A, et al. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. Hematol J. 2004;5(6):475-9.
16. Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessi C, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica. 2005;90(10):1309-14. Comment in: Haematologica. 2005;90(10):1297A.
17. Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol. 2006;85(5):315-9.
18. Kattamis A, Ladis V, Berdousi H, Kelekis NL, Alexopoulou E, Papasotiriou I, et al. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells Mol Dis. 2006;36(1):21-5.
19. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88(5):489-96. Comment in: Haematologica. 2003;88(5):481-2.
20. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107(9):3733-7.
21. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of deferiprone or desferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738-44.
22. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876-84.
23. Tsironi M, Deftereos S, Andriopoulos P, Farmakis D, Meletis J, Aessopos A. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. Eur J Haematol. 2005;74(1):84-5.
24. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000;95(4):1229-36.
25. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006;107(9):3436-41.
26. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455-62. Comment in: Blood. 2006;108(5):1775-6; Blood. 2006;108(2):774-5; Blood. 2006;108(2):778.
27. Deugnier Y, Turlin B, Ropert M, Cappellini MD, Porter JB, Giannone V, et al. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years. Gastroenterology. 2011;141(4):1202-11, 1211.e1-3. Comment in: Gastroenterology. 2011;141(4):1142-3.
28. Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood. 2011;118(4):884-93.
29. Eleftheriou P, Tanner M, Pennel D, Porter JB. Response of myocardial T2* to oral deferasirox monotherapy for 1 year in 29 patients with transfusion-dependent anaemias; a subgroup analysis. Haematologica. 2006;91(s1):366
30. Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010;115(12):2364-71. Comment in: Blood. 2010;115(12):2333-4.
31. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, et al. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica 2011;96(1):48-54. Comment in: Haematologica. 2011;96(1):5-8.
32. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica. 2012;97(6):842-8.
33. Assis RA de, Ribeiro AA, Kay FU, Rosemberg LA, Nomura CH, Loggetto SR, et al. Pancreatic iron stores assessed by magnetic resonance imaging (MRI) in beta thalassemic patients. Eur J Radiol. 2012;81(7):1465-70.
34. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103(5):1934-6.
35. Wood JC, Origa R, Agus A, Matta G, Coates TD, Galanello R. Onset of cardiac iron loading in pediatric patients with thalassemia major. Haematologica. 2008;93(6):917-20. Comment in: Haematologica. 2009;94(12):1776-7.
36. Fernandes JL, Fabron A Jr, Verissimo M. Early cardiac iron overload in children with transfusion-dependent anemias. Haematologica. 2009;94(12):1776-7. Comment on: Haematologica. 2008;93(6):917-20.
37. Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta. 1996;1275(3):161-203.
38. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995;332(14):918-22. Comment in: N Engl J Med. 1995;333(9):597-8; N Engl J Med. 1995;333(9):598; N Engl J Med. 1995;332(14):953-4.
39. Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann N Y Acad Sci. 1998;850:191-201.
40. Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD, Coates TD. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106(4):1460-5.
41. Cappellini MD, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A, editors. Guidelines for the Clinical Management of Thalassaemia [Internet]. 2nd rev ed. Cyprus: Thalassaemia International Federation; 2008. [cited 2011 Sep 21]. Available from:http://www.thalassaemia.org.cy/wordpress/wp-content/uploads/2012/12/Guidelines-2nd-edition-revised-ENGLISH-lo.pdf
42. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171-9. Comment in: Eur Heart J. 2001;22(23):2140-1.
43. Ghugre NR, Enriquez CM, Coates TD, Nelson MD Jr, Wood JC. Improved R2* measurements in myocardial iron overload. J Magn Reson Imaging. 2006;23(1):9-16.
44. Fernandes JL, Sampaio EF, Verissimo M, Pereira FB, da Silva JA, Figueiredo GS et al. Heart and liver T2* assessment for iron overload using different software programs. Eur Radiol. 2011;21(12):2503-10.
45. Hankins JS, McCarville MB, Loeffler RB, Smeltzer MP, Onciu M, Hoffer FA, et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood. 2009;113(20):4853-5.
46. Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, Noronha SV de, et al. On T2* magnetic resonance and cardiac iron. Circulation. 2011;123(14):1519-28.
47. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148(3):466-75. Comment in: Br J Haematol. 2010;150(4):489-90.
48. Porter JB, Piga A, Cohen A, Ford JM, Bodner J, Rojkjaer L, et al. Safety of deferasirox (Exjade®) in patients with transfusion-dependent anemias and iron overload who achieve serum ferritin levels < 1000 ng/mL during long-term treatment. Blood (ASH Annual Meeting Abstracts) [Internet]. 2008;112(11):abstract 5423. [cited 2012 Mar 21]. Available from: http://abstracts.hematologylibrary.org/cgi/content/abstract/112/11/5423?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=piga+a&searchid=1&FIRSTINDEX=0&volume=112&issue=11&resourcetype=HWCIT
49. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102(5):1583-7.
50. al-Refaie FN, Wonke B, Hoffbrand AV. Deferiprone-associated myelotoxicity. Eur J Haematol. 1994;53(5):298-301.
51. Projeto Diretrizes: Associação Médica Brasileira e Conselho Federal de Medicina. São Paulo. [cited 2011 Sep 14] Available from: http://www.projetodiretrizes.org.br/projeto_diretrizes/texto_introdutorio.pdf
52. Fargion S, Fracanzani AL, Rossini A, Borzio M, Riggio O, Belloni G, et al. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol. 2002;97(5):1204-10. Comment in: Am J Gastroenterol. 2002;97(5):1093-6.
53. Angelucci E, Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev J, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002;100(1):17-21.
54. Hershko C. Pathogenesis and management of iron toxicity in thalassemia. Ann N Y Acad Sci. 2010;1202:1-9.
55. Piga A, Longo F, Duca L, Roggero S, Vinciguerra T, Calabrese R, et al. High non transferrin bound iron levels and heart disease in thalassemia major. Am J Hematol. 2009;84(1):29-33.
56. Farmaki K, Tzoumari I, Pappa C. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Mol Dis. 2011;47(1):33-40.